How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%

Janux Therapeutics carries a consensus price target implying 180.4% upside, but the article cautions that price targets are often ineffective predictors. The more constructive signal is an upward trend in earnings estimate revisions, which could support near-term upside in the stock. Overall, the piece is a bullish analyst commentary rather than a company-specific catalyst.

Analysis

Janux Therapeutics carries a consensus price target implying 180.4% upside, but the article cautions that price targets are often ineffective predictors. The more constructive signal is an upward trend in earnings estimate revisions, which could support near-term upside in the stock. Overall, the piece is a bullish analyst commentary rather than a company-specific catalyst.